Gilead price target lowered to $156 from $157 at Truist

Truist lowered the firm's price target on Gilead to $156 from $157 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.